What Does Sevabertinib's Expanded Approval Mean for HER2+ NSCLC?

In September 2026, the FDA granted accelerated approval to sevabertinib as a frontline treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer harboring HER2 tyrosine kinase domain mutations, expanding its indication from prior second-line use. This approval reflects ongoing advances in precision oncology for HER2-mutated NSCLC and highlights the importance of genetic testing to identify suitable patients for targeted therapies.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 9 Sep 2026 and 5 Oct 2026.